Gedea Biotech has raised 11 MSEK for clinical trials throughout 2018, to verify the treatment of vaginal infections. The share issue has attracted a large interest from investors and was expanded from estimated 7 MSEK to 11 MSEK.
Read more
Newsletter
Sign up for our newsletter >